TOT Biopharm (HKG:1875) turned to a yearly profit for the first time, logging 34.8 million yuan in 2024 from a loss of 37.8 million yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.
The antibody and ADC drugs production turned to earnings per share of 0.05 yuan from a loss per share of 0.05 yuan in the previous year.
Revenue grew 41% to about 1.10 billion yuan from 780.6 million yuan a year earlier.
Shares fell 3% during Wednesday's morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.